Ultragenyx Pharmaceutical Inc. revenue for the last year amounted to 434.25 M USD, the most of which — 182.65 M USD — came from its highest performing source at the moment, Crysvita Royalty, the year earlier bringing 21.69 M USD. The greatest contribution to the revenue figure was made by North America — last year it brought Ultragenyx Pharmaceutical Inc. 307.15 M USD, and the year before that — 281.09 M USD.